[COGENTINE (BTMS) IN THE TREATMENT OF NEUROLEPTIC SYNDROMES].
D014150:Antipsychotic Agents; D001714:Bipolar Disorder; D002746:Chlorpromazine; D003693:Delirium; D003863:Depression; D006212:Hallucinations; D006220:Haloperidol; D006801:Humans; D001523:Mental Disorders; D008728:Methotrimeprazine; D010276:Parasympatholytics; D010640:Phenothiazines; D011618:Psychotic Disorders; D012559:Schizophrenia; D013577:Syndrome; D013881:Thioridazine; D014149:Tranquilizing Agents; D014268:Trifluoperazine; D014291:Trimeprazine
D014150:Antipsychotic Agents; D010276:Parasympatholytics; D010640:Phenothiazines; D014149:Tranquilizing Agents; D014268:Trifluoperazine; C084584:periciazine; D014291:Trimeprazine; D008728:Methotrimeprazine; D006220:Haloperidol; D013881:Thioridazine; D002746:Chlorpromazine; C084825:thioproperazine
CHLORPROMAZINE; DELIRIUM; DEPRESSION; HALLUCINATIONS; HALOPERIDOL; MENTAL DISORDERS; METHOTRIMEPRAZINE; PARASYMPATHOLYTICS; PROPERICIAZINE; PSYCHOSES, MANIC-DEPRESSIVE; SCHIZOPHRENIA; THIOPROPERAZINE; THIORIDAZINE; TRANQUILIZING AGENTS; TRIFLUOPERAZINE; TRIMEPRAZINE
LA COGENTINE (BTMS) DANS LE TRAITEMENT DES SYNDROMES NEUROLEPTIQUES